Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Jaguar Health Inc (JAGX)
Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,069
  • Shares Outstanding, K 50,756
  • Annual Sales, $ 11,960 K
  • Annual Income, $ -47,450 K
  • 60-Month Beta 1.68
  • Price/Sales 1.50
  • Price/Cash Flow N/A
  • Price/Book 4.73
Trade JAGX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.19
  • Most Recent Earnings -0.38 on 11/14/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 145.53%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,445.36% on 04/06/23
  • IV Low 0.00% on 12/01/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 233
  • Volume Avg (30-Day) 285
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 9,151
  • Open Int (30-Day) 8,268

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2578 +38.09%
on 11/07/23
0.5144 -30.79%
on 11/20/23
+0.0085 (+2.45%)
since 11/01/23
3-Month
0.2100 +69.52%
on 10/16/23
0.5290 -32.70%
on 10/12/23
-0.0205 (-5.44%)
since 09/01/23
52-Week
0.2100 +69.52%
on 10/16/23
9.7500 -96.35%
on 12/02/22
-9.3940 (-96.35%)
since 12/01/22

Most Recent Stories

More News
FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU

/CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or "Filament Health"), a clinical-stage natural psychedelic drug development...

FLHLF : 0.1291 (-3.44%)
JAGX : 0.3560 (+0.62%)
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

/CNW/ - Jaguar Health, Inc. (NASDAQ: JAGX), Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) and One Small Planet, LLC today announced the formation of a...

JAGX : 0.3560 (+0.62%)
FLHLF : 0.1291 (-3.44%)
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions

Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee

JAGX : 0.3560 (+0.62%)
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / July 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 27, 2022, the Company granted 60,000 restricted stock...

JAGX : 0.3560 (+0.62%)
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months

JAGX : 0.3560 (+0.62%)
Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi

SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress,...

JAGX : 0.3560 (+0.62%)
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1

Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from...

JAGX : 0.3560 (+0.62%)
Jaguar Health Announces Publication of Onco'Zine Article Underscoring the Importance of Controlling Diarrhea in Cancer Patients

Diarrhea is also a prevalent side effect in dogs undergoing cancer treatment; managing diarrhea can be important to maintain successful cancer treatment in both humans and dogs

JAGX : 0.3560 (+0.62%)
Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders

All Proposals Approved

JAGX : 0.3560 (+0.62%)
Jaguar Health to Participate in BIO International Convention (BIO 2022)

Jaguar seeking partnering meetings at BIO 2022 related to the company's novel plant-based FDA-approved anti-secretory agent for cancer therapy-related diarrhea (CTD) and inflammatory bowel disease (IBD)...

JAGX : 0.3560 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

3rd Resistance Point 0.3742
2nd Resistance Point 0.3670
1st Resistance Point 0.3615
Last Price 0.3560
1st Support Level 0.3488
2nd Support Level 0.3416
3rd Support Level 0.3361

See More

52-Week High 9.7500
Fibonacci 61.8% 6.1057
Fibonacci 50% 4.9800
Fibonacci 38.2% 3.8543
Last Price 0.3560
52-Week Low 0.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar